Beam Therapeutics Profit margin
What is the Profit margin of Beam Therapeutics?
The Profit margin of Beam Therapeutics Inc. is -35.09%
What is the definition of Profit margin?
Profit margin is a measure of profitability and is calculated by finding the net profit as a percentage of the revenue.
lfy (last fiscal year)
Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.
Profit margin of companies in the Health Care sector on NASDAQ compared to Beam Therapeutics
What does Beam Therapeutics do?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Companies with profit margin similar to Beam Therapeutics
- Raunaq EPC International has Profit margin of -35.31%
- Hempstract has Profit margin of -35.31%
- Mobecom has Profit margin of -35.25%
- China Merchants Commercial Real Estate Investment Trust has Profit margin of -35.23%
- Cambium Networks Corp has Profit margin of -35.16%
- E-Land Apparel has Profit margin of -35.10%
- Beam Therapeutics has Profit margin of -35.09%
- Suncity has Profit margin of -35.09%
- The Motor & General Finance has Profit margin of -35.06%
- Inox Leisure has Profit margin of -35.01%
- PopReach has Profit margin of -34.99%
- Brooks Laboratories has Profit margin of -34.98%
- Paramount Inc has Profit margin of -34.97%